Literature DB >> 7821750

Oligosaccharide-protein interactions in IgG can modulate recognition by Fc gamma receptors.

J Lund1, N Takahashi, J D Pound, M Goodall, H Nakagawa, R Jefferis.   

Abstract

X-ray crystal structures of IgG-Fc provide evidence of extensive noncovalent interactions between the protein and carbohydrate moieties, and glycosylation, at Asn-297 within the Fc, has been shown to be important for effector functions mediated through Fc gamma receptors expressed on leukocytes. We have applied protein engineering in an attempt to define protein/carbohydrate interactions essential to wild-type biological activity. We demonstrate that replacement of Lys-246, Asp-249, and Glu-258, which make contacts with GlcNac and Gal on the outer alpha[1-->6] arm, do not affect recognition of human chimeric IgG3 by human Fc gamma RI and Fc gamma RII. However, replacement of Asp-265, which make contacts with the primary GlcNac sugar residue and is covalently attached to Asn-297, resulted in loss of recognition of both Fc gamma RI and Fc gamma RII. Similarly, replacement of Asp-265 in mouse IgG2b resulted in loss of recognition by mouse Fc gamma RII. These results suggest that noncovalent contacts of Asp-265 with the primary GlcNac residue are important for maintenance of recognition of IgG by Fc gamma receptors whereas contacts with GlcNac and Gal on the alpha [1-->6] arm do not have a measurable effect. This conclusion was supported by experiments in which galactose-deficient and fully galactosylated forms of a human IgG4-Fc fragment were shown to be equivalent in their ability to inhibit superoxide generation by IgG4 stimulated U937 cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7821750     DOI: 10.1096/fasebj.9.1.7821750

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  10 in total

1.  Basic problems of serological laboratory diagnosis.

Authors:  W Fierz
Journal:  Mol Biotechnol       Date:  1999-12-01       Impact factor: 2.695

Review 2.  Extracellular enzymes with immunomodulating activities: variations on a theme in Streptococcus pyogenes.

Authors:  Mattias Collin; Arne Olsén
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

3.  Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities.

Authors:  Shan Chung; Valerie Quarmby; Xiaoying Gao; Yong Ying; Linda Lin; Chae Reed; Chris Fong; Wendy Lau; Zhihua J Qiu; Amy Shen; Martin Vanderlaan; An Song
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

4.  The history of IgG glycosylation and where we are now.

Authors:  Brian A Cobb
Journal:  Glycobiology       Date:  2020-03-20       Impact factor: 4.313

5.  Glycosylation of polyclonal and paraprotein IgG in multiple myeloma.

Authors:  M Farooq; N Takahashi; H Arrol; M Drayson; R Jefferis
Journal:  Glycoconj J       Date:  1997-06       Impact factor: 2.916

6.  The glycosylation pattern of humanized IgGI antibody (D1.3) expressed in CHO cells.

Authors:  F H Routier; M J Davies; K Bergemann; E F Hounsell
Journal:  Glycoconj J       Date:  1997-02       Impact factor: 2.916

7.  The Structural Role of Antibody N-Glycosylation in Receptor Interactions.

Authors:  Ganesh P Subedi; Adam W Barb
Journal:  Structure       Date:  2015-07-23       Impact factor: 5.006

8.  Fc gamma receptor CD64 modulates the inhibitory activity of infliximab.

Authors:  Kacper A Wojtal; Gerhard Rogler; Michael Scharl; Luc Biedermann; Pascal Frei; Michael Fried; Achim Weber; Jyrki J Eloranta; Gerd A Kullak-Ublick; Stephan R Vavricka
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

9.  Construction of a stability landscape of the CH3 domain of human IgG1 by combining directed evolution with high throughput sequencing.

Authors:  Michael W Traxlmayr; Christoph Hasenhindl; Matthias Hackl; Gerhard Stadlmayr; Jakub D Rybka; Nicole Borth; Johannes Grillari; Florian Rüker; Christian Obinger
Journal:  J Mol Biol       Date:  2012-07-27       Impact factor: 5.469

Review 10.  Fc glycans of therapeutic antibodies as critical quality attributes.

Authors:  Dietmar Reusch; Max L Tejada
Journal:  Glycobiology       Date:  2015-08-11       Impact factor: 4.313

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.